Abstract
The research project aims to develop an ex vivo platform to assess the effectiveness of drugs in samples from adult patients with acute lymphoblastic leukemia (ALL) within the context of a clinical study. The goal is to correlate drug responses with genetic, proteomic, metabolic, and clinical-laboratory characteristics. Peripheral blood and bone marrow samples from ALL patients diagnosed …